TY - JOUR
T1 - Dysregulation of threat neurociruitry during fear extinction
T2 - the role of anhedonia
AU - Young, Katherine S.
AU - Bookheimer, Susan Y.
AU - Nusslock, Robin
AU - Zinbarg, Richard E.
AU - Damme, Katherine S.F.
AU - Chat, Iris Ka Yi
AU - Kelley, Nicholas J.
AU - Vinograd, Meghan
AU - Perez, Marcelina
AU - Chen, Kelly
AU - Cohen, Aileen Echiverri
AU - Craske, Michelle G.
N1 - Funding Information:
This work was supported by the National Institute of Mental Health (NIMH) of the National Institutes of Health (NIH) under award number R01MH100117, awarded to MGC, SYB, RN, and REZ.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/8
Y1 - 2021/8
N2 - Dimensional models of anxiety and depression highlight common and distinct symptom clusters that are thought to reflect disruptions in underlying functional processes. The current study investigated how functioning of threat neurocircuitry relates to symptom dimensions of anxiety and depression. Participants were aged 18–19 years (n = 229, 158 female) and were selected to ensure a range of scores on symptom measures. Symptom dimensions of “General Distress” (common to anxiety disorders and depression), “Fears” (more specific to anxiety disorders), and “Anhedonia-apprehension” (more specific to depression) were evaluated. Participants underwent functional magnetic resonance imaging during a Pavlovian fear conditioning paradigm. Multilevel modeling analyses estimated relationships between symptom dimensions and activation in threat neural circuitry. Exploratory whole brain analyses were also conducted. Threat-related neural activity was not associated with General Distress or Fears. Anhedonia-apprehension was associated with activation of bilateral amygdala, anterior insula and dACC during late extinction. We found no evidence to support an association between symptom dimensions of General Distress or Fears with threat circuitry activation in a large sample of young adults. We did, however, find that the symptom dimension of Anhedonia-apprehension was significantly associated with threat-related neural activation during fear extinction. This effect requires replication in future work but may reflect anhedonic impairments in learning when contingencies are altered, possibly linked to the rewarding relief of an unexpectedly absent threat.
AB - Dimensional models of anxiety and depression highlight common and distinct symptom clusters that are thought to reflect disruptions in underlying functional processes. The current study investigated how functioning of threat neurocircuitry relates to symptom dimensions of anxiety and depression. Participants were aged 18–19 years (n = 229, 158 female) and were selected to ensure a range of scores on symptom measures. Symptom dimensions of “General Distress” (common to anxiety disorders and depression), “Fears” (more specific to anxiety disorders), and “Anhedonia-apprehension” (more specific to depression) were evaluated. Participants underwent functional magnetic resonance imaging during a Pavlovian fear conditioning paradigm. Multilevel modeling analyses estimated relationships between symptom dimensions and activation in threat neural circuitry. Exploratory whole brain analyses were also conducted. Threat-related neural activity was not associated with General Distress or Fears. Anhedonia-apprehension was associated with activation of bilateral amygdala, anterior insula and dACC during late extinction. We found no evidence to support an association between symptom dimensions of General Distress or Fears with threat circuitry activation in a large sample of young adults. We did, however, find that the symptom dimension of Anhedonia-apprehension was significantly associated with threat-related neural activation during fear extinction. This effect requires replication in future work but may reflect anhedonic impairments in learning when contingencies are altered, possibly linked to the rewarding relief of an unexpectedly absent threat.
UR - http://www.scopus.com/inward/record.url?scp=85104064210&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104064210&partnerID=8YFLogxK
U2 - 10.1038/s41386-021-01003-8
DO - 10.1038/s41386-021-01003-8
M3 - Article
C2 - 33833400
AN - SCOPUS:85104064210
SN - 0893-133X
VL - 46
SP - 1650
EP - 1657
JO - Neuropsychopharmacology
JF - Neuropsychopharmacology
IS - 9
ER -